IE32405L - Dehydroepiandrosterone esters - Google Patents

Dehydroepiandrosterone esters

Info

Publication number
IE32405L
IE32405L IE118468A IE118468A IE32405L IE 32405 L IE32405 L IE 32405L IE 118468 A IE118468 A IE 118468A IE 118468 A IE118468 A IE 118468A IE 32405 L IE32405 L IE 32405L
Authority
IE
Ireland
Prior art keywords
oestrogen
preparations
esters
complaints
preferred
Prior art date
Application number
IE118468A
Other versions
IE32405B1 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IE32405L publication Critical patent/IE32405L/en
Publication of IE32405B1 publication Critical patent/IE32405B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1,246,639. Medicines comprising steroids. SCHERING A.G. 30 Sept., 1968 [4 Oct., 1967], No. 46299/68. Heading A5B. [Also in Division C2] Pharmaceutical preparations, suitable for the treatment of climacteric complaints, osteoporosis, deafness due to old age, blood perfusion complaints, heart diseases and depressive states, comprise novel esters of 3 #-hydroxy-#<SP>5</SP>-androsten-17-one with C 7-14 aliphatic carboxylic acids and suitable carriers and/or an oestrogen. Preferred esters are the oenanthate and undecylenate and a preferred oestrogen is oestradiol 17-valerate. Dosage units generally contain 50-500 mg., preferably 100-300 mg., of the ester, and 0.5-10, preferably about 4; mg. of the oestrogen. The preparations are normally in a form suitable for intramuscular infection e.g. oily solutions such as in sesame or castor oil; diluents and/or solubilizing agents e.g. benzyl benzoate, may also be added. Preparations for oral administration are also referred to. [GB1246639A]
IE118468A 1967-10-04 1968-10-03 Dehydroepiandrosterone esters IE32405B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DESC041382 1967-10-04

Publications (2)

Publication Number Publication Date
IE32405L true IE32405L (en) 1969-04-04
IE32405B1 IE32405B1 (en) 1973-07-25

Family

ID=7436199

Family Applications (1)

Application Number Title Priority Date Filing Date
IE118468A IE32405B1 (en) 1967-10-04 1968-10-03 Dehydroepiandrosterone esters

Country Status (12)

Country Link
AT (1) AT297946B (en)
BE (1) BE721825A (en)
BR (1) BR6802861D0 (en)
CS (1) CS150596B2 (en)
DK (1) DK122125B (en)
FI (1) FI45551C (en)
FR (2) FR1584879A (en)
GB (1) GB1246639A (en)
IE (1) IE32405B1 (en)
NL (1) NL160835C (en)
SE (1) SE352347B (en)
YU (1) YU33834B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63267722A (en) * 1987-04-27 1988-11-04 Daiichi Yakuhin Sangyo Kk Anti-obesity agent
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
ATE275957T1 (en) * 1993-01-19 2004-10-15 Endorech Inc THERAPEUTIC USES AND ADMINISTRATION SYSTEMS OF DEHYDROEPIANDROSTERONE
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN110585124A (en) * 2019-09-26 2019-12-20 西安力邦医药科技有限责任公司 An oily injection containing estriol or its derivatives

Also Published As

Publication number Publication date
FI45551C (en) 1972-07-10
AT297946B (en) 1972-03-15
FR8191M (en) 1970-09-07
BE721825A (en) 1969-04-04
SE352347B (en) 1972-12-27
DK122125B (en) 1972-01-24
DE1643046B2 (en) 1975-11-27
BR6802861D0 (en) 1973-03-15
DE1643046A1 (en) 1971-06-16
FI45551B (en) 1972-04-04
GB1246639A (en) 1971-09-15
FR1584879A (en) 1970-01-02
YU33834B (en) 1978-06-30
NL160835B (en) 1979-07-16
NL6814196A (en) 1969-04-09
NL160835C (en) 1979-12-17
CS150596B2 (en) 1973-09-04
YU224068A (en) 1977-12-31
IE32405B1 (en) 1973-07-25

Similar Documents

Publication Publication Date Title
IE32405L (en) Dehydroepiandrosterone esters
DE69004532T2 (en) Medicinal preparations containing topical defibrotide.
Menkin Further Studies on Effect of Adrenal Cortex Extract and of Various Steroids on Capillary Permeability.
FI67298B (en) FRAMEWORK FOR THERAPEUTIC AVERAGE THERAPEUTIC REQUIREMENT FOR STEROID
US4181721A (en) Depot preparations in an oily, unsaturated solution for intramuscular injection
Bennett The debatable benefit of occlusive dressings for wounds
Anderson et al. Comparative pulmonary surfactant-inducing effect of three corticosteroids in the near-term rat
FELDMAN et al. Effect of prolonged use of estrogens on circulating lipids in patients with idiopathic hyperlipemia or idiopathic hypercholesteremia
US4076811A (en) Novel agents and methods for treatment of climacteric disturbances
van den Hoogenband et al. PUVA therapy in the treatment of skin lesions of the hypereosinophilic syndrome
ASADA et al. Effect of ovariectomy on serum lipid peroxide levels in women
Goodman et al. Hepatocellular carcinoma in association with androgen therapy
GB1193464A (en) Steroidal Esters, Processes for Making them, and Therapeutic Compositions Containing them
GB1483650A (en) Pharmaceutical preparations based on mesterolone
Hall Clinical experiences with the sublingual administration of alpha estradiol
FRANK et al. HYDROCORTISONE (COMPOUND F) FREE ALCOHOL AND HYDROCORTISONE ACETATE FOR TOPICAL USE: A Clinical Evaluation
GB1505879A (en) Acylated orgotein
Heimann et al. EFFECTS OF PLASMOQUIN, ATEBRIN, AND QUININE ON THE ELECTROCARDIOGRAM
Crompton et al. Pulmonary fibrosis, mimicking tuberculosis, presenting before joint symptoms in a female with ankylosing spondylitis
Lipschütz et al. Comparative Conjunctive Tumorigenic Action of Three Different Esters of Estradiol.
US3754086A (en) Stable oily preparations of epithio-steroids
Lassus Local treatment of psoriasis with clobetasol propionate and betamethasone-17, 21 dipropionate: A double-blind comparison
GB1472086A (en) Pharmaceutical composition for treatment of liver diseases
Grunt et al. In vivo observations of the seminal vesicles of castrated rats and the responses to various steroids
PRATT et al. ORAL AND RECTAL THYMOLYTIC ACTIVITIES OF SOME ANTI-INFLAMMATORY STEROIDS IN WEANLING RATS